316 related articles for article (PubMed ID: 16634075)
21. In vitro and in vivo photosensitizing applications of Photofrin in malignant melanoma cells.
Chang CJ; Yu JS; Wei FC
Chang Gung Med J; 2008; 31(3):260-7. PubMed ID: 18782948
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous two-photon excitation of photofrin in relation to photodynamic therapy.
Karotki A; Khurana M; Lepock JR; Wilson BC
Photochem Photobiol; 2006; 82(2):443-52. PubMed ID: 16613497
[TBL] [Abstract][Full Text] [Related]
23. Tissue distribution and pharmacokinetics of an ATWLPPR-conjugated chlorin-type photosensitizer targeting neuropilin-1 in glioma-bearing nude mice.
Thomas N; Tirand L; Chatelut E; Plénat F; Frochot C; Dodeller M; Guillemin F; Barberi-Heyob M
Photochem Photobiol Sci; 2008 Apr; 7(4):433-41. PubMed ID: 18385885
[TBL] [Abstract][Full Text] [Related]
24. Biodistribution of Photofrin II and 5-aminolevulinic acid-induced protoporphyrin IX in normal rat bladder and bladder tumor models: implications for photodynamic therapy.
Xiao Z; Miller GG; McCallum TJ; Brown KM; Lown JW; Tulip J; Moore RB
Photochem Photobiol; 1998 May; 67(5):573-83. PubMed ID: 9613241
[TBL] [Abstract][Full Text] [Related]
25. Topical use of liposomal copper palmitate formulation blocks porphyrin-induced photosensitivity in rats.
Bilgin MD; Elçin AE; Elçin YM
J Photochem Photobiol B; 2005 Aug; 80(2):107-14. PubMed ID: 15893469
[TBL] [Abstract][Full Text] [Related]
26. Modeling of a type II photofrin-mediated photodynamic therapy process in a heterogeneous tissue phantom.
Hu XH; Feng Y; Lu JQ; Allison RR; Cuenca RE; Downie GH; Sibata CH
Photochem Photobiol; 2005; 81(6):1460-8. PubMed ID: 15960591
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
Chan AL; Juarez M; Allen R; Volz W; Albertson T
Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
[TBL] [Abstract][Full Text] [Related]
28. Accumulation of photofrin in lesions of airway stenosis rabbit models.
Nakagishi Y; Morimoto Y; Fujita M; Ozeki Y; Maehara T; Kikuchi M
Photochem Photobiol; 2007; 83(5):1220-5. PubMed ID: 17880518
[TBL] [Abstract][Full Text] [Related]
29. Aminolaevulinic acid diffusion characteristics in 'in vitro' normal human skin and actinic keratosis: implications for topical photodynamic therapy.
McLoone N; Donnelly RF; Walsh M; Dolan OM; McLoone S; McKenna K; McCarron PA
Photodermatol Photoimmunol Photomed; 2008 Aug; 24(4):183-90. PubMed ID: 18717959
[TBL] [Abstract][Full Text] [Related]
30. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up.
Tschen EH; Wong DS; Pariser DM; Dunlap FE; Houlihan A; Ferdon MB;
Br J Dermatol; 2006 Dec; 155(6):1262-9. PubMed ID: 17107399
[TBL] [Abstract][Full Text] [Related]
31. Systemic application of photosensitizers in the chick chorioallantoic membrane (CAM) model: photodynamic response of CAM vessels and 5-aminolevulinic acid uptake kinetics by transplantable tumors.
Hornung R; Hammer-Wilson MJ; Kimel S; Liaw LH; Tadir Y; Berns MW
J Photochem Photobiol B; 1999 Mar; 49(1):41-9. PubMed ID: 10365445
[TBL] [Abstract][Full Text] [Related]
32. A preliminary pharmacokinetic study of intravenous Photofrin in patients.
Bellnier DA; Dougherty TJ
J Clin Laser Med Surg; 1996 Oct; 14(5):311-4. PubMed ID: 9612197
[TBL] [Abstract][Full Text] [Related]
33. An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy.
Henderson BW; Bellnier DA; Greco WR; Sharma A; Pandey RK; Vaughan LA; Weishaupt KR; Dougherty TJ
Cancer Res; 1997 Sep; 57(18):4000-7. PubMed ID: 9307285
[TBL] [Abstract][Full Text] [Related]
34. Characterization of Photofrin photobleaching for singlet oxygen dose estimation during photodynamic therapy of MLL cells in vitro.
Dysart JS; Patterson MS
Phys Med Biol; 2005 Jun; 50(11):2597-616. PubMed ID: 15901957
[TBL] [Abstract][Full Text] [Related]
35. Our PDT experience in the treatment of non-melanoma skin cancer over the last 7 years.
Baptista J; Martinez C; Leite L; Cochito M
J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):693-7. PubMed ID: 16836497
[TBL] [Abstract][Full Text] [Related]
36. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2.
Liu W; Baer MR; Bowman MJ; Pera P; Zheng X; Morgan J; Pandey RA; Oseroff AR
Clin Cancer Res; 2007 Apr; 13(8):2463-70. PubMed ID: 17438106
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo efficacy of photofrin and pheophorbide a, a bacteriochlorin, in photodynamic therapy of colonic cancer cells.
Hajri A; Wack S; Meyer C; Smith MK; Leberquier C; Kedinger M; Aprahamian M
Photochem Photobiol; 2002 Feb; 75(2):140-8. PubMed ID: 11883602
[TBL] [Abstract][Full Text] [Related]
38. Bioadhesive patch-based delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis.
Donnelly RF; McCarron PA; Lightowler JM; Woolfson AD
J Control Release; 2005 Mar; 103(2):381-92. PubMed ID: 15763621
[TBL] [Abstract][Full Text] [Related]
39. [Porfimer sodium (Photofrin-II)].
Tsukagoshi S
Gan To Kagaku Ryoho; 1995 Aug; 22(9):1271-8. PubMed ID: 7661580
[TBL] [Abstract][Full Text] [Related]
40. A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumors in C3H mice.
Anderson CY; Freye K; Tubesing KA; Li YS; Kenney ME; Mukhtar H; Elmets CA
Photochem Photobiol; 1998 Mar; 67(3):332-6. PubMed ID: 9523532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
